Moomoo AIのまとめ
Intelligent Bio Solutions Inc. (INBS) reported financial results for the quarter ended March 31, 2024. Revenue increased to $823,800, up from $457,058 in the same period last year, driven by the expansion of the customer base and entry into new markets. Cost of revenue also rose to $645,311, resulting in a gross profit of $178,489. The company received $83,842 in government support income. Operating expenses totaled $3,216,066, with selling, general and administrative expenses accounting for $2,425,830. Development and regulatory approval expenses were $471,313, and depreciation and amortization expenses were $318,923. The company did not report any goodwill impairment for the quarter. Other income and expenses included an interest expense of $42,674 and a realized foreign exchange loss of $996. The net loss for the quarter was $2,986,765, with a loss per share of $1.43. The...Show More
Intelligent Bio Solutions Inc. (INBS) reported financial results for the quarter ended March 31, 2024. Revenue increased to $823,800, up from $457,058 in the same period last year, driven by the expansion of the customer base and entry into new markets. Cost of revenue also rose to $645,311, resulting in a gross profit of $178,489. The company received $83,842 in government support income. Operating expenses totaled $3,216,066, with selling, general and administrative expenses accounting for $2,425,830. Development and regulatory approval expenses were $471,313, and depreciation and amortization expenses were $318,923. The company did not report any goodwill impairment for the quarter. Other income and expenses included an interest expense of $42,674 and a realized foreign exchange loss of $996. The net loss for the quarter was $2,986,765, with a loss per share of $1.43. The company's cash and cash equivalents stood at $9,397,523, with working capital of $5,814,284. INBS raised approximately $10.76 million through a warrant inducement transaction and a private placement offering. The company's future plans include continuing its FDA 510(k) clinical studies plan, expanding its customer base, and discussing future licensing of SGT products with the University of Newcastle following the liquidation of its licensor, LSBD.
Intelligent Bio Solutions Inc.（INBS）は、2024年3月31日終了の四半期に関する財務結果を発表しました。収益は、顧客基盤の拡大と新市場への進出により、前年同期の457,058ドルから823,800ドルに増加しました。収益原価も645,311ドルに上昇し、粗利益は178,489ドルとなりました。同社はレジスタンス収入として83,842ドルを受け取りました。営業費用は合計で3,216,066ドルであり、うち販売・一般・管理費用が2,425,830ドルを占めました。開発・規制承認費用は471,313ドルであり、減価償却費と摊余費用は318,923ドルでした。同社は...すべて展開
Intelligent Bio Solutions Inc.（INBS）は、2024年3月31日終了の四半期に関する財務結果を発表しました。収益は、顧客基盤の拡大と新市場への進出により、前年同期の457,058ドルから823,800ドルに増加しました。収益原価も645,311ドルに上昇し、粗利益は178,489ドルとなりました。同社はレジスタンス収入として83,842ドルを受け取りました。営業費用は合計で3,216,066ドルであり、うち販売・一般・管理費用が2,425,830ドルを占めました。開発・規制承認費用は471,313ドルであり、減価償却費と摊余費用は318,923ドルでした。同社は四半期において無形資産の減損に関しては報告していません。その他の収益や費用には、利息費用が42,674ドル、実現された外国為替損失が996ドルが含まれています。四半期の純損失は2,986,765ドルで、1株当たりの損失は1.43ドルとなりました。同社の現金及び現金同等物は9,397,523ドルで、運転資本は5,814,284ドルでした。INBSは、ウォラント誘引取引および非公募発行により、およそ1076万ドルを調達しました。同社の将来の計画には、FDA 510（k）臨床試験計画を継続し、顧客基盤の拡大、LSBDの許諾者の清算に伴うニューカッスル大学とのSGt製品の将来的なライセンスに関する協議が含まれます。
役に立った
役に立たない